Icosavax, Inc. (ICVX)

NASDAQ: ICVX · IEX Real-Time Price · USD
3.29
+0.21 (6.82%)
Nov 29, 2022 4:00 PM EDT - Market closed
6.82%
Market Cap 122.89M
Revenue (ttm) 6.38M
Net Income (ttm) -86.33M
Shares Out 39.75M
EPS (ttm) 0.11
PE Ratio 29.91
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 51,712
Open 3.13
Previous Close 3.08
Day's Range 3.11 - 3.51
52-Week Range 2.28 - 26.66
Beta n/a
Analysts Buy
Price Target 28.56 (+768.1%)
Earnings Date Nov 21, 2022

About ICVX

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411,... [Read more]

Industry Biotechnology
IPO Date Jul 29, 2021
Employees 34
Stock Exchange NASDAQ
Ticker Symbol ICVX
Full Company Profile

Financial Performance

In 2021, Icosavax's revenue was $7.80 million, an increase of 382.80% compared to the previous year's $1.62 million. Losses were -$66.97 million, 255.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ICVX stock is "Buy." The 12-month stock price forecast is 28.56, which is an increase of 768.09% from the latest price.

Price Target
$28.56
(768.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Icosavax to Participate in the Evercore ISI HealthCONx Conference

SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against ...

1 week ago - GlobeNewsWire

Icosavax, Inc. (ICVX) Reports Q3 Loss, Lags Revenue Estimates

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of 3.51% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Icosavax Reports Third Quarter Financial Results and Provides Corporate Update

- Initiated a Phase 1 trial of Icosavax's first combination bivalent vaccine candidate, IVX-A12, against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults -

2 weeks ago - GlobeNewsWire

Icosavax to Participate in in Upcoming Investor Conferences

SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against ...

3 weeks ago - GlobeNewsWire

Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults

- IVX-A12 is the first combination bivalent vaccine candidate against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to reach clinical stage -

1 month ago - GlobeNewsWire

Icosavax, Inc. (ICVX) Reports Q2 Loss, Lags Revenue Estimates

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of -3.64% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Icosavax Reports Second Quarter 2022 Financial Results and Provides Corporate Update

– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) -

3 months ago - GlobeNewsWire

Icosavax Announces Results from IVX-411 Drug Product Investigation and Outlines Additional Corporate Milestones

- Antigen component of IVX-411 found to be unstable; issue specific to molecule, with no evidence of read-through to other Icosavax programs -

4 months ago - GlobeNewsWire

Icosavax to Participate in the William Blair Biotech Focus Conference

SEATTLE, July 06, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against ...

4 months ago - GlobeNewsWire

Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups -

5 months ago - GlobeNewsWire

Icosavax to Participate in the Jefferies Healthcare Conference

SEATTLE, June 01, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop combination vaccines ag...

5 months ago - GlobeNewsWire

Icosavax Reports First Quarter 2022 Financial Results and Provides Corporate Update

- Enrollment completed in older adults portion of Phase 1/1b trial of IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antig...

6 months ago - GlobeNewsWire

Why Icosavax Stock Is Soaring Today

The company's Q4 update made investors feel a little better after receiving disappointing news last week.

7 months ago - The Motley Fool

Icosavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

- Completed dosing in older adults portion of Phase 1/1b clinical trial for IVX-121, a VLP vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen -

7 months ago - GlobeNewsWire

Icosavax posts COVID-19 vaccine data ‘below our expectations' as shares plummet

Seattle-based vaccine company Icosavax posted disappointing clinical data today for its experimental COVID-19 vaccine, sending its stock into a dive.

8 months ago - GeekWire

Why Icosavax's Shares Are Trading Lower Today

Icosavax Inc (NASDAQ: ICVX) has announced topline interim results from its ongoing Phase 1/2 trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD). In the naï...

8 months ago - Benzinga

Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2

- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company's platform and VLP technology; end-to-end...

8 months ago - GlobeNewsWire

Icosavax to Participate in the Cowen 42nd Annual Health Care Conference

SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against...

8 months ago - GlobeNewsWire

Icosavax Provides Corporate Update and Anticipated Milestones for 2022

SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against ...

10 months ago - GlobeNewsWire

Icosavax Appoints Dr. John Shiver to Board of Directors

- Dr. Shiver has contributed to the licensure of 14 pharmaceutical addressing global infectious diseases - - Dr. Shiver has contributed to the licensure of 14 pharmaceutical addressing global infectious...

10 months ago - GlobeNewsWire

Icosavax Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- Initiated a Phase 1/1b clinical trial for IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen -

1 year ago - GlobeNewsWire

Icosavax to Participate in Upcoming Investor Conferences

SEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against ...

1 year ago - GlobeNewsWire

Icosavax co-founder and UW researcher Neil King talks vaccine development in the ‘digital era'

We are now in the “digital era” of vaccine development, University of Washington researcher Neil King said at the GeekWire Summit in Seattle on Tuesday.

1 year ago - GeekWire

Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update

- Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain -

1 year ago - GlobeNewsWire

Icosavax Appoints Elizabeth Bekiroğlu to General Counsel

SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against...

1 year ago - GlobeNewsWire